FTC supplements settlement
This article was originally published in The Tan Sheet
Executive Summary
Gero Vita International and six related defendants are required to pay monetary judgments of $605,000 after settling Federal Trade Commission charges related to deceptive marketing practices, FTC reports June 8. The defendants, including dietary supplement direct marketer Almon Glenn Braswell, claimed their products could cure or treat illnesses and conditions such as diabetes, Alzheimer's disease and obesity, the agency says. FTC originally filed the complaint in May 2003 (1"The Tan Sheet" June 2, 2003, p. 13). The defendants are barred from making future misleading product claims in addition to the fines. The $605,000 settlement resulted from the suspension of a $30 mil. judgment based on the defendants' inability to pay. However, the defendants will have to pay the total $30 mil. if they misrepresented their financial condition or Braswell does business with any other defendant, FTC says...
You may also be interested in...
Braswell Supplement Operations Charged With False Advertising By FTC
Dietary supplement direct marketer Almon Glenn Braswell and four of his corporations falsely represented New Life Nutrition magazine as an "independent publication and not paid advertising," according to an 1FTC complaint filed in Los Angeles federal court May 27
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.